The Ministry of Health, Labour and Welfare (MHLW) of Japan has approved to sell Insulin Glargine for which company

2016

Please wait while the activity loads.
If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.

If loading fails, click here to try again

Question [CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]

A	Sanofi Aventis
B	Eli Lilly and Company (India) Pvt Ltd
C	Biocon India Ltd
D	None of the above

Explanation:

Detailed explanation-1: -BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S. | Eli Lilly and Company.

Detailed explanation-2: -Lantus-Insulin Glargine Latest Price, Dealers & Retailers in India.

Detailed explanation-3: -Basaglar®, Abasaglar® and KwikPen® are registered trademarks of Eli Lilly and Company . Lantus® is a registered trademark of sanofi-aventis U.S. LLC .

Detailed explanation-4: -Semglee (insulin glargine-yfgn), the first interchangeable biosimilar insulin product, was approved by the FDA in July 2021. This product is interchangeable with Lantus (insulin glargine), its reference product. This means that Semglee may be used in place of Lantus without obtaining the prescriber’s approval.

There is 1 question to complete.